0001562180-23-008519.txt : 20231221 0001562180-23-008519.hdr.sgml : 20231221 20231221133805 ACCESSION NUMBER: 0001562180-23-008519 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231219 FILED AS OF DATE: 20231221 DATE AS OF CHANGE: 20231221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mills Kenneth T. CENTRAL INDEX KEY: 0001652824 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 231504389 MAIL ADDRESS: STREET 1: C/O REGENXBIO INC. STREET 2: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471851754 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2023-12-19 false 0001590877 REGENXBIO Inc. RGNX 0001652824 Mills Kenneth T. C/O REGENXBIO INC. 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 true true false false President and CEO true Common Stock 2023-12-19 4 M false 43500.00 3.76 A 398789.00 D Common Stock 2023-12-19 4 M false 1500.00 0.85 A 400289.00 D Common Stock 2023-12-19 4 S false 45000.00 19.685 D 355289.00 D Stock Options (Right to Buy) 3.76 2023-12-19 4 M false 43500.00 0.00 D 2025-05-19 Common Stock 43500.00 186354.00 D Stock Options (Right to Buy) 0.85 2023-12-19 4 M false 1500.00 0.00 D 2024-09-24 Common Stock 1500.00 36316.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $19.48 to $20.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The previously granted option, representing a right to purchase a total of 43,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 9, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. The previously granted option, representing a right to purchase a total of 1,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on September 24, 2015, and the balance vested in equal monthly installments over the 36 months thereafter. /s/ Patrick J. Christmas as attorney-in-fact 2023-12-21